The Scientific Basis of Body Surface Area-Based Dosing

被引：22
作者：
Chatelut, E. [1 ,2 ]
Puisset, F. [1 ,2 ]
机构：
[1] Inst Claudius Regaud, Dept Pharmacol, Toulouse, France
[2] Univ Toulouse, Toulouse, France
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷 / 04期
关键词：
POPULATION PHARMACOKINETICS; CANCER-PATIENTS; BREAST-CANCER; PHARMACODYNAMICS; PACLITAXEL; ONCOLOGY; WEIGHT;
D O I：
10.1038/clpt.2014.7
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：359 / 361
页数：3
相关论文
共 15 条
  • [1] Bruno R., 1996, PHARMACOKINET BIOPHA, V24, P153
  • [2] Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
    Chatelut, E.
    White-Koning, M. L.
    Mathijssen, R. H. J.
    Puisset, F.
    Baker, S. D.
    Sparreboom, A.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 107 (07) : 1100 - 1106
  • [3] Population pharmacokinetics of cisplatin in adult cancer patients
    de Jongh, FE
    Gallo, JM
    Shen, MY
    Verweij, J
    Sparreboom, A
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (02) : 105 - 112
  • [4] Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer
    Deporte-Fety, R
    Simon, N
    Fumoleau, P
    Campone, M
    Kerbrat, P
    Bonneterre, J
    Fargeot, P
    Urien, S
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (03) : 233 - 238
  • [5] Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
    Griggs, Jennifer J.
    Mangu, Pamela B.
    Anderson, Holly
    Balaban, Edward P.
    Dignam, James J.
    Hryniuk, William M.
    Morrison, Vicki A.
    Pini, T. May
    Runowicz, Carolyn D.
    Rosner, Gary L.
    Shayne, Michelle
    Sparreboom, Alex
    Sucheston, Lara E.
    Lyman, Gary H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) : 1553 - 1561
  • [6] Gumey H, 1996, J CLIN ONCOL, V14, P2590
  • [7] Hirth J, 2000, CLIN CANCER RES, V6, P1255
  • [8] Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients:: A study by the EORTC-PAMM-NDDG
    Joerger, Markus
    Huitema, Alwin D. R.
    Richel, Dick J.
    Dittrich, Christian
    Pavlidis, Nikolas
    Briasoulis, Evangelos
    Vermorken, Jan B.
    Strocchi, Elena
    Martoni, Andrea
    Sorio, Roberto
    Sleeboom, Henk P.
    Izquierdo, Miguel A.
    Jodrell, Duncan I.
    Fety, Regine
    de Bruijn, Ernst
    Hempel, Georg
    Karlsson, Mats
    Tranchand, Brigitte
    Schrijvers, Ad H. G. J.
    Twelves, Chris
    Beijnen, Jos H.
    Schellens, Jan H. M.
    [J]. CLINICAL PHARMACOKINETICS, 2007, 46 (12) : 1051 - 1068
  • [9] Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients
    Latz, JE
    Chaudhary, A
    Ghosh, A
    Johnson, RD
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (04) : 401 - 411
  • [10] Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and leukemia group B study 9763
    Miller, AA
    Rosner, GL
    Egorin, MJ
    Hollis, D
    Lichtman, SM
    Ratain, MJ
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (24) : 8325 - 8331
12